Skip to main content
PharmGen Science, Inc. logo

PharmGen Science, Inc. — Investor Relations & Filings

Ticker · 004720 ISIN · KR7004720009 KO Manufacturing
Open in API
Filings indexed 296 across all filing types
Latest filing 2022-05-04 Director's Dealing
Country KR South Korea
Listing KO 004720

About PharmGen Science, Inc.

http://www.pharmgenscience.com/en/

PharmGen Science, Inc. is a pharmaceutical company engaged in the research, development, production, and sale of medicaments. The company's portfolio encompasses a range of prescription (ETC) and over-the-counter (OTC) drugs, including analgesics, antibiotics, and anti-inflammatory agents. A key strategic focus for the company is the discovery and development of novel drugs for gastrointestinal (GI) disorders. PharmGen Science aims to provide integrated pharmaceutical solutions by leveraging its diverse infrastructure and global network.

Recent filings

Filing Released Lang Actions
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). It details the share ownership changes of an executive (Lee Hae-doo) at PharmGen Science. This type of filing is a standard regulatory requirement for insider trading or changes in holdings by company directors/executives, which corresponds to the 'Director's Dealing' category.
2022-05-04 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled '정기주주총회결과' (Annual General Meeting Results) and provides a detailed breakdown of the voting outcomes for various agenda items, including the approval of financial statements, election of directors, and remuneration limits. Since it reports the official results of shareholder votes at an Annual General Meeting, it falls under the category of Declaration of Voting Results.
2022-03-29 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing titled 'Audit Report Submission' (감사보고서 제출) from PharmGen Science. It provides the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, profit) for both consolidated and separate financial statements. While it contains financial data, it is a summary disclosure of the audit results rather than the full annual report (10-K) or a standalone audit report document. In the context of Korean regulatory filings (DART/KIND), this is a standard disclosure announcement regarding the receipt and submission of the audit report. FY 2021
2022-03-21 Korean
사업보고서 (2021.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 56th fiscal period (2021), which is the standard terminology for an Annual Report in the South Korean regulatory framework (DART). It contains comprehensive company information, financial data, and management details, fitting the definition of a 10-K equivalent. FY 2021
2022-03-21 Korean
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) regarding a 'Notice of Convocation of General Meeting of Shareholders' (주주총회소집공고). It details specific corrections made to the agenda items and candidate information for the upcoming Annual General Meeting (AGM). While it contains financial statements, these are provided as part of the meeting materials for shareholder review. Since the document is primarily focused on the logistics and agenda of the AGM, it is classified as AGM Information.
2022-03-21 Korean
[기재정정]의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (의결권대리행사권유참고서류) filed by PharmGen Science. It contains details regarding the upcoming Annual General Meeting (AGM), including corrections to candidate information and financial statements (balance sheets, income statements, cash flow statements) intended for shareholder review prior to the meeting. While it contains financial data, it is specifically a proxy statement for the AGM, not a standalone 10-K or Annual Report.
2022-03-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.